Phaseline

Targets › HCRTR2

HCRTR2 (Orexin receptor type 2): drug programs, companies and trials

12 programs from 12 companies in 31 trials: 15 Phase 2, 8 Phase 4, 5 Phase 3, 3 Phase 1; Neurology, Psychiatry, Respiratory; next expected readout Dec 2026.

G protein-coupled receptor that binds neuropeptides orexin-A and orexin-B, two neuropeptides derived from a common precursor, prepro-orexin. Upon neuropeptide ligand binding, HCRTR2 can couple with both G(q)/11 and G(i)/o heterotrimeric G proteins thereby initiating distinct downstream signaling cascades. (UniProt, O43614)

Open in Phaseline: the race on HCRTR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The University of Texas Health Science Center, HoustonALA 10% gel
Muscle-type nicotinic acetylcholine receptor antagonist
HCRTR2, HCRTR1, CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE, HTR2A, PTGS2, PTGS1Phase 4Anesthesia; Cleft Lip and Palate; Pancreatic Ductal Adenocarcinoma (PDAC); Stimulant Use Disorder …Dec 2026
Stanford UniversityLemborexant
Orexin receptor 1 antagonist; Orexin receptor 2 antagonist
HCRTR1, HCRTR2Phase 4Delayed Sleep Phase SyndromeMay 2027
Mahidol UniversityLemborexant
Orexin receptor 1 antagonist; Orexin receptor 2 antagonist
HCRTR1, HCRTR2Phase 4Sleep DisturbanceDec 2027
Nova Scotia Health AuthorityLemborexant
Orexin receptor 1 antagonist; Orexin receptor 2 antagonist
HCRTR1, HCRTR2Phase 4InsomniaDec 2028
Johnson & Johnson (Janssen)Seltorexant
Orexin receptor 2 antagonist
HCRTR2Phase 3Depressive Disorder, MajorDec 2026
University of ManitobaLemborexant
Orexin receptor 1 antagonist; Orexin receptor 2 antagonist
HCRTR1, HCRTR2Phase 3EpilepsyApr 2027
Merck & Co. (MSD)Suvorexant (MK-4305)
Orexin receptor antagonist
HCRTR2, HCRTR1Phase 3Insomnia; Alcohol Use Disorder (AUD); Suicide Risk; Autism …Jun 2027
Idorsia PharmaceuticalsDaridorexant
Orexin receptor antagonist; Orexin receptor 1 antagonist; Orexin receptor 2 antagonist
HCRTR2, HCRTR1Phase 3Insomia Disorder; Learning; Alzheimer Disease; Postoperative Cognitive Decline …Nov 2027
Flinders UniversityLemborexant
Orexin receptor 1 antagonist; Orexin receptor 2 antagonist
HCRTR1, HCRTR2Phase 2OSA - Obstructive Sleep ApneaMay 2027
Woolcock Institute of Medical ResearchLemborexant
Orexin receptor 1 antagonist; Orexin receptor 2 antagonist
HCRTR1, HCRTR2Phase 2InsomniaDec 2027
Virginia Commonwealth UniversityLemborexant
Orexin receptor 1 antagonist; Orexin receptor 2 antagonist
HCRTR1, HCRTR2Phase 2Opioid Use DisorderJul 2029
University of MinnesotaLemborexant
Orexin receptor 1 antagonist; Orexin receptor 2 antagonist
HCRTR1, HCRTR2Phase 2Alzheimer DiseaseMar 2030

Conditions

Insomnia (4) Alzheimer Disease (2) Depressive Disorder, Major (2) Insomia Disorder (1) Learning (1) Postoperative Cognitive Decline (1) Alzheimer Disease (AD) (1) Epilepsy (1) Delayed Sleep Phase Syndrome (1) Alcohol Use Disorder (AUD) (1) Suicide Risk (1) Autism (1)

Modalities

small molecule (12)

Companies

Idorsia Pharmaceuticals (1) University of Manitoba (1) Johnson & Johnson (Janssen) (1) Stanford University (1) Merck & Co. (MSD) (1) Virginia Commonwealth University (1) Flinders University (1) University of Minnesota (1) Mahidol University (1) Woolcock Institute of Medical Research (1) The University of Texas Health Science Center, Houston (1) Nova Scotia Health Authority (1)

Related targets

HCRTR1 (11) CHRNA1 (1) CHRNG (1) CHRNB1 (1) CHRND (1) CHRNE (1) HTR2A (1) PTGS2 (1) PTGS1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.